Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Asthma Health Center

Font Size

Xolair Gets 'Black Box' Warning

Asthma Drug's Packaging Warns of Potentially Severe Allergic Reaction
WebMD Health News
Reviewed by Louise Chang, MD

July 3, 2007 -- The asthma drug Xolair has a new "black box" warning about severe, potentially life-threatening allergic reaction (anaphylaxis).

In February, the FDA requested Xolair's maker, Genentech, to put the boxed warning on Xolair. Now, those warnings have been added to Xolair's packaging.

Black box warnings are the FDA's sternest warning for prescription drug labels.

The new warning notes reports of anaphylaxis in patients taking Xolair. Those reports include new users of Xolair and patients who have been taking the asthma drug for longer than one year, according to the FDA.

The FDA notes that due to the risk of anaphylaxis, Xolair should only be administered to patients under direct medical supervision by health care workers who are aware of Xolair's anaphylaxis risk, monitor patients taking Xolair, and are prepared to treat anaphylaxis.

Xolair is given by injection to patients who are at least 12 years old and have moderate-to-severe persistent allergic asthma that doesn't respond to inhaled corticosteroids.

Patients taking Xolair should be informed about their chances of developing anaphylaxis, note the FDA and Genentech.

The warning notes that signs and symptoms of anaphylaxis can include the following:

Patients experiencing such symptoms should seek emergency medical care.

The FDA notes three cases of anaphylaxis among 3,507 patients taking Xolair in the drug's premarketing clinical trials.

The FDA also states that in a review of 124 case reports among some 57,300 patients who took Xolair from June 2003 to December 2006, the frequency of anaphylaxis attributed to Xolair was estimated to be at least 0.2% of treated patients.

When Is Your Asthma Worse?

When Is Your Asthma Worse?

Take the WebMD Asthma assessment to get Personalized Action Plan

Start Now

Today on WebMD

Lung and bronchial tube graphic
5 common triggers.
group jogging in park
Should you avoid fitness activities?
asthma inhaler
Learn about your options.
man feeling faint
What’s the difference?
Madison Wisconsin Capitol
woman wearing cpap mask
red wine pouring into glass
Woman holding inhaler
Man outdoors coughing
Lung and bronchial tube graphic
10 Worst Asthma Cities